$104.81
+0.34
(+0.33%)▲
0.66%
Downside
Day's Volatility :1.31%
Upside
0.65%
2.68%
Downside
52 Weeks Volatility :23.82%
Upside
21.73%
Period | Zimmer Biomet Holdings, Inc. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -7.53% | 5.1% | 1.1% |
6 Months | -17.71% | 4.9% | 4.9% |
1 Year | -13.03% | 16.6% | 21.5% |
3 Years | -28.52% | 13.2% | 19.7% |
Market Capitalization | 21.3B |
Book Value | $62.18 |
Dividend Share | 0.96 |
Dividend Yield | 0.92% |
Earnings Per Share (EPS) | 4.79 |
PE Ratio | 21.88 |
PEG Ratio | 1.38 |
Wall Street Target Price | 125.28 |
Profit Margin | 13.25% |
Operating Margin TTM | 20.71% |
Return On Assets TTM | 4.54% |
Return On Equity TTM | 7.95% |
Revenue TTM | 7.5B |
Revenue Per Share TTM | 36.37 |
Quarterly Revenue Growth YOY | 3.9% |
Gross Profit TTM | 4.9B |
EBITDA | 2.5B |
Diluted Eps TTM | 4.79 |
Quarterly Earnings Growth YOY | 0.18 |
EPS Estimate Current Year | 8.05 |
EPS Estimate Next Year | 8.65 |
EPS Estimate Current Quarter | 1.99 |
EPS Estimate Next Quarter | 1.87 |
What analysts predicted
Upside of 19.53%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.9B | ↑ 1.39% |
Net Income | -379.2M | ↓ 120.61% |
Net Profit Margin | -4.78% | ↓ 28.29% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 8.0B | ↑ 0.62% |
Net Income | 1.1B | ↓ 398.42% |
Net Profit Margin | 14.18% | ↑ 18.96% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 7.0B | ↓ 12.0% |
Net Income | -137.4M | ↓ 112.14% |
Net Profit Margin | -1.96% | ↓ 16.14% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 6.8B | ↓ 2.81% |
Net Income | 401.6M | ↓ 392.29% |
Net Profit Margin | 5.88% | ↑ 7.84% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 6.9B | ↑ 1.65% |
Net Income | 231.4M | ↓ 42.38% |
Net Profit Margin | 3.33% | ↓ 2.55% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 7.4B | ↑ 6.55% |
Net Income | 1.0B | ↑ 342.52% |
Net Profit Margin | 13.85% | ↑ 10.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.8B | ↑ 0.32% |
Net Income | 232.5M | ↓ 278.57% |
Net Profit Margin | 12.7% | ↑ 19.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↑ 2.11% |
Net Income | 209.6M | ↓ 9.85% |
Net Profit Margin | 11.21% | ↓ 1.49% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.8B | ↓ 6.2% |
Net Income | 162.7M | ↓ 22.38% |
Net Profit Margin | 9.28% | ↓ 1.93% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↑ 10.64% |
Net Income | 419.2M | ↑ 157.65% |
Net Profit Margin | 21.61% | ↑ 12.33% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↓ 2.62% |
Net Income | 172.4M | ↓ 58.87% |
Net Profit Margin | 9.13% | ↓ 12.48% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↑ 2.79% |
Net Income | 242.8M | ↑ 40.84% |
Net Profit Margin | 12.5% | ↑ 3.37% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 24.1B | ↓ 8.58% |
Total Liabilities | 12.9B | ↓ 12.19% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 24.6B | ↑ 2.12% |
Total Liabilities | 12.2B | ↓ 4.71% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 24.4B | ↓ 0.9% |
Total Liabilities | 12.2B | ↓ 0.23% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 23.5B | ↓ 3.94% |
Total Liabilities | 10.8B | ↓ 11.69% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 21.1B | ↓ 10.19% |
Total Liabilities | 9.0B | ↓ 16.23% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 21.5B | ↑ 2.05% |
Total Liabilities | 9.0B | ↓ 0.34% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 21.2B | ↑ 0.84% |
Total Liabilities | 9.1B | ↑ 0.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 21.3B | ↑ 0.24% |
Total Liabilities | 8.9B | ↓ 1.87% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 21.2B | ↓ 0.36% |
Total Liabilities | 8.7B | ↓ 2.43% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 21.5B | ↑ 1.32% |
Total Liabilities | 9.0B | ↑ 3.56% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 21.5B | ↓ 0.21% |
Total Liabilities | 8.8B | ↓ 1.8% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 21.5B | ↑ 0.32% |
Total Liabilities | 8.8B | ↓ 0.86% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.7B | ↑ 10.43% |
Investing Cash Flow | -416.6M | ↓ 18.44% |
Financing Cash Flow | -1.3B | ↑ 7.58% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.6B | ↓ 9.25% |
Investing Cash Flow | -729.3M | ↑ 75.06% |
Financing Cash Flow | -779.9M | ↓ 40.11% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.2B | ↓ 24.04% |
Investing Cash Flow | -613.8M | ↓ 15.84% |
Financing Cash Flow | -421.8M | ↓ 45.92% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↑ 24.47% |
Investing Cash Flow | -503.6M | ↓ 17.95% |
Financing Cash Flow | -1.3B | ↑ 209.63% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.3B | ↓ 14.31% |
Investing Cash Flow | -529.2M | ↑ 5.08% |
Financing Cash Flow | -843.8M | ↓ 35.39% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 307.7M | ↑ 26.0% |
Investing Cash Flow | -149.4M | ↓ 71.77% |
Financing Cash Flow | -206.7M | ↓ 34.05% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 347.9M | ↑ 13.06% |
Investing Cash Flow | -392.5M | ↑ 162.72% |
Financing Cash Flow | -109.4M | ↓ 47.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 337.6M | ↓ 2.96% |
Investing Cash Flow | -558.1M | ↑ 42.19% |
Financing Cash Flow | -196.0M | ↑ 79.16% |
Sell
Neutral
Buy
Zimmer Biomet Holdings, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Zimmer Biomet Holdings, Inc. | -0.95% | -17.71% | -13.03% | -28.52% | -23.54% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Zimmer Biomet Holdings, Inc. | 21.88 | 21.88 | 1.38 | 8.05 | 0.08 | 0.05 | 0.01 | 62.18 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Zimmer Biomet Holdings, Inc. | Hold | $21.3B | -23.54% | 21.88 | 13.25% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Zimmer Biomet Holdings, Inc.
Revenue is up for the last 2 quarters, 1.88B → 1.94B (in $), with an average increase of 2.7% per quarter
Netprofit is up for the last 2 quarters, 172.4M → 242.8M (in $), with an average increase of 29.0% per quarter
In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 64.4%
In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 109.4%
Vanguard Group Inc
BlackRock Inc
Dodge & Cox
T. Rowe Price Associates, Inc.
State Street Corporation
Amvescap Plc.
In the quarter ending March,2024. Zimmer Biomet Holdings, Inc. has declared dividend of $0.24
Read Morezimmer biomet is the world’s most trusted brand for personalized bone and joint healthcare solutions. we help people discover and achieve exceptional outcomes. as a leading innovator in musculoskeletal healthcare, we offer a complete portfolio of products for joint reconstruction, bone and skeletal repair, sports medicine, spine, and dental reconstruction. every day, we focus on improving musculoskeletal healthcare. it’s all we do. it’s all we’ve ever done. for nearly 90 years, zimmer biomet has helped people progress beyond their pain and limitations. because it’s not just what we make, it’s what we make possible. zimmer biomet serves healthcare professionals and their patients globally. our worldwide headquarters is in warsaw, indiana, usa.
Organization | Zimmer Biomet Holdings, Inc. |
Employees | 18000 |
CEO | Mr. Ivan Tornos |
Industry | Health Technology |
Sirius Xm Holdings Inc.
$104.81
+0.33%
Cognizant Technology Solutions Corp.
$104.81
+0.33%
Globalfoundries Inc.
$104.81
+0.33%
Deckers Outdoor Corp.
$104.81
+0.33%
Bxp Inc
$104.81
+0.33%
Realty Income Corporation
$104.81
+0.33%
Gold Shares Spdr
$104.81
+0.33%
Vertiv Holdings Co
$104.81
+0.33%
S&p Dividend Spdr
$104.81
+0.33%